CD274 and non-small cell lung carcinoma: Silibinin treatment inhibited the upregulation of the programmed death-ligand 1(PD-L1) and EMT regulators in crizotinib-resistance cells, suggesting a potential improvement of ALK TKI resistant NSCLC patients with silibinin-based drugs [145].